Adaptive Biotechnologies (ADPT) shares surged nearly 37% in recent Friday trading, a day after the company reported a narrower loss and higher revenue in Q1.
The company reported a Q1 diluted loss late Thursday of $0.20 per share, narrowing from a loss of $0.33 a year earlier.
Analysts polled by FactSet expected a loss of $0.29.
Revenue for the quarter ended March 31 was $52.4 million, up from $41.9 million a year earlier.
Analysts surveyed by FactSet expected $42.7 million.
The company raised its full-year revenue guidance for the Minimal Residual Disease business to $180 million to $190 million from $175 million to $185 million previously. The company did not provide revenue guidance for its Immune Medicine business.
Analysts surveyed by FactSet expect total revenue of $216 million for the year.
The company also said it now expects full-year total company cash burn at $50 million to $60 million, versus $60 million to $70 million previously.
Price: 10.06, Change: +2.70, Percent Change: +36.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。